JavaScript seem to be disabled in your browser.
You must have JavaScript enabled in your browser to utilize the functionality of this website.
Abrezekimab is a humanized monoclonal antibody that targets IL-13 in development for asthma. It was designed as a high-affinity antibody fragment suitable for inhalation, to provide a more rapid onset of action at lower doses than subcutaneous systemic administration.